{"url_path":"/sec/rare/8-k/2026-05-18/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements and Exhibits.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-18","source_url":"https://www.sec.gov/Archives/edgar/data/1515673/0001193125-26-228639-index.html","accession_number":"0001193125-26-228639","cik":"0001515673","ticker":"RARE","issuer_name":"Ultragenyx Pharmaceutical Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1515673/0001193125-26-228639-index.html","primary_entity_key":"0001515673","primary_entity_name":"Ultragenyx Pharmaceutical Inc."},"word_count":91,"has_tables":true,"body_markdown":"## Item 9.01 Financial Statements and Exhibits.\n\n(d) Exhibits\n\nExhibit No.\n\nDescription\n\n10.1\n\n[Third Amended and Restated 2023 Incentive Plan](rare-ex10_1.htm)\n\n104\n\nThe cover page from the Company’s Current Report on Form 8-K dated May 14, 2026 formatted in Inline XBRL.\n\n \n\n \n\n \n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n \n\n \n\n \n\nUltragenyx Pharmaceutical Inc.\n\n \n\n \n\n \n\n \n\nDate:\n\nMay 18, 2026\n\nBy:\n\n/s/ Howard Horn\n\n \n\n \n\n \n\nHoward Horn\nExecutive Vice President, Chief Financial Officer, Corporate Strategy"}